General Counsel
Iovance Biotherapeutics, Inc. (IOVA)Equibles does not estimate personal net worth.
Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IOVA alertsFrederick Vogt is recorded as CEO and General Counsel at Iovance Biotherapeutics, Inc. (IOVA). The newest filing on record that lists Frederick Vogt as CEO at Iovance Biotherapeutics, Inc. (IOVA) is dated April 28, 2026. The newest filing on record that lists Frederick Vogt as General Counsel at Iovance Biotherapeutics, Inc. (IOVA) is dated April 27, 2021. Frederick Vogt has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Iovance Biotherapeutics, Inc. on September 15, 2026. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Corleen Roche (CFO), Jean-Marc Bellemin (CFO) and 7 others.
“In 2025, IVANCE delivered substantial revenue growth, achieved groundbreaking data milestones, and strengthened our financial performance. Our fourth quarter and full year 2025 results underscore our focus on value creation for patients and shareholders.”
“Iovance is the global leader in innovating, developing, and delivering pill therapy for solid tumors, today and for the next generation. The second quarter of 2026 was our strongest yet.”
“I am pleased to host our first quarter 2024 results conference call. This has been a decisive year for Iovance following our first FDA approval and a strong start to the U.S. launch of Amtagvi for patients with advanced melanoma.”
“I'm pleased to share some significant recent milestones at Iovance. We are making substantial progress toward U.S. commercialization while exploring opportunities for our TIL therapies in other regions for solid tumor cancers.”
“I’m pleased to highlight some great momentum at Iovance. We are getting ready to complete our biologics license application, or BLA, submission for our lead cell therapies like lifileucel and advanced melanoma while preparing for commercialization and developing our robust immune oncology pipeline.”
Start not stated–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 27, 2021
Biotechnology · Healthcare
CEO, General Counsel
